prescribing in pregnancy and lactation
Untreated maternal disease is often the bigger foetal risk — don’t stop essential therapy without a substitute. FDA A–X letter categories are retired. Know the short teratogen list, reconcile every medication at delivery (the safe list changes), and check LactMed for breastfeeding. Most drugs are compatible with breastfeeding; codeine, tramadol, DOACs, amiodarone, and cytotoxics are the exceptions to know.
ACEi/ARB/ARNI/DRI (T2–T3 fetopathy), warfarin (6–12 wk embryopathy; except mechanical valves), valproate, carbamazepine, phenytoin, topiramate, methotrexate, mycophenolate, leflunomide (washout), cyclophosphamide, isotretinoin, thalidomide/lenalidomide, tetracyclines (after 15 wk), statins (avoid), SGLT2i/GLP-1 RA (no data), DOACs, lithium (Ebstein — modest; continue if needed), radioactive iodine, misoprostol.
pharmacokinetics — what changes dosing
- ↑ volume of distribution, ↓ albumin → ↑ free fraction (phenytoin: use free level)
- GFR ↑ ~50% → ↑ clearance of LMWH, levetiracetam, lithium, many antibiotics
- Hepatic: ↑ CYP3A4, CYP2D6, UGT (lamotrigine ↓↓); ↓ CYP1A2 (caffeine, theophylline ↑)
- Reverses within 1–3 wk postpartum → dose-reduce LTG, lithium, insulin, β-blockers
- Placental transfer: small, lipophilic, unbound molecules cross; heparins, insulin, large biologics (until IgG transfer late T3) don’t
by condition
| condition | use | avoid / restrict |
|---|---|---|
| hypertension | labetalol, nifedipine XL, methyldopa, hydralazine | ACEi, ARB, DRI, atenolol, spironolactone |
| VTE / anticoagulation | LMWH, UFH, aspirin | DOACs; warfarin except mechanical valves |
| diabetes | insulin, metformin, glyburide | SGLT2i, GLP-1 RA, DPP-4i, other SUs, TZDs |
| epilepsy | lamotrigine, levetiracetam, oxcarbazepine | valproate, topiramate, phenytoin/phenobarbital |
| asthma | ICS, ICS–LABA, SABA, montelukast, prednisone, biologics | stopping controllers |
| thyroid | levothyroxine; PTU in T1 → methimazole from T2 | radioactive iodine; methimazole in T1 (embryopathy) |
| autoimmune / IBD | hydroxychloroquine (continue), prednisone, azathioprine, sulfasalazine (+ folate), 5-ASA, tacrolimus, cyclosporin, IVIG, colchicine, TNF inhibitors | methotrexate (stop 1–3 months before), mycophenolate (stop ≥6 wk before), leflunomide (cholestyramine washout), cyclophosphamide, JAK inhibitors |
| infection | penicillins, cephalosporins, azithromycin, clindamycin, carbapenems, metronidazole, nitrofurantoin (not near term), vancomycin | tetracyclines, FQs, TMP-SMX (T1/late T3), aminoglycosides (ototoxicity) unless needed |
| analgesia | acetaminophen; opioids short-term | NSAIDs ≥20 wk (oligohydramnios) and especially ≥28–30 wk (ductus closure) |
| GI | doxylamine–pyridoxine, dimenhydrinate, metoclopramide, ondansetron, H2RA, PPI, calcium carbonate | — |
| psychiatric | SSRIs (continue if needed — sertraline most data), lithium with monitoring | paroxetine (cardiac — avoid starting), valproate |
| opioid use disorder | continue methadone or buprenorphine | abrupt withdrawal |
- Hydroxychloroquine in SLE: continue — stopping ↑ flares and worsens pregnancy outcomes
- Antenatal steroids for foetal lung maturity: betamethasone/dexamethasone; maternal steroids: prednisone/prednisolone (placenta inactivates ~90%)
breastfeeding
| class | compatible | avoid / caution |
|---|---|---|
| antihypertensives | labetalol, methyldopa, nifedipine, enalapril, captopril (SOGC); metoprolol | atenolol (infant bradycardia); ARB, ARNI (no data) |
| anticoagulants | LMWH, UFH, warfarin, danaparoid | DOACs |
| diabetes | insulin, metformin, glyburide | SGLT2i, GLP-1 RA (no data) |
| analgesia | acetaminophen, ibuprofen (preferred NSAID), short-course morphine/hydromorphone | codeine, tramadol (CYP2D6 ultra-rapid metabolisers → infant opioid toxicity/death) |
| antiseizure | lamotrigine, levetiracetam, carbamazepine, valproate | phenobarbital, benzodiazepines (infant sedation) |
| cardiac | most β-blockers, digoxin, furosemide, spironolactone | amiodarone, ivabradine, statins |
| other | most antibiotics, SSRIs, HCQ, azathioprine, prednisone, TNF inhibitors | lithium (infant levels/TSH — specialist), cytotoxics, radioactive iodine |
- Iodinated and gadolinium contrast: no need to interrupt breastfeeding
- Oestrogen-containing contraception ↓ milk supply and ↑ VTE <6 wk postpartum → progestin-only/IUD first
postpartum medication reconciliation
- Insulin: drop below pre-pregnancy dose at placenta delivery
- Lamotrigine/levetiracetam: taper over 1–3 wk
- Antihypertensives: escalate day 3–7 (BP peak), wean after; switch to enalapril if proteinuria
- HF: start full GDMT within breastfeeding limits — peripartum cardiomyopathy
- Anticoagulation: continue ≥6 wk postpartum where indicated; warfarin acceptable
- β-blockers for arrhythmia: down-titrate as HR falls
- Restart drugs stopped for pregnancy (ACEi, statin after breastfeeding)
- Contraception plan with every teratogen
LactMed (breastfeeding), MotherToBaby and BUMPS (pregnancy, patient handouts), Reprotox (subscription). UpToDate still shows retired FDA letter categories — don’t use them.
infective endocarditis prophylaxis at delivery
- Not recommended for vaginal or caesarean delivery, even with high-risk cardiac lesions (ESC/AHA) — standard obstetric surgical prophylaxis still applies
- Prophylaxis remains for dental procedures in high-risk patients (prosthetic valves/material, prior IE, unrepaired cyanotic CHD) — see infective endocarditis
Prepared 2026-10-15. Not yet verified — check every number against the sources.